Literature DB >> 32200102

Engineering antigen as photosensitiser nanocarrier to facilitate ROS triggered immune cascade for photodynamic immunotherapy.

Huaiji Wang1, Kun Wang1, Lianghua He1, Ying Liu1, Haiqing Dong2, Yongyong Li3.   

Abstract

Despite of the documented immunogenic cell death (ICD) and antigen cross-presentation (AC) in photodynamic therapy (PDT), the overall immune efficacy is rather limited. This study aims to expand the immune potential of PDT by spatially packaging antigen as photosensitiser nanocarrier to trigger efficient immune cascade for photodynamic immunotherapy. The package of ovalbumin antigen (OVA) into sub-100 nm nano-assembly is realized by driving intermolecular disulfide network between OVA molecules. OVA nanoparticles loading photosensitiser Ce6 (ON) are subsequently coated with B16-OVA cancer cell membrane, resulting in membrane cloaked ON (MON). Importantly, laser irradiation generated ROS significantly potentiates OVA antigen cross-presentation efficiency. Whilst, MON is endowed with homophilic targeting towards tumor due to cancer cell membrane coating. In treating B16-OVA tumor-bearing mice, MON effectively triggers the immune cascade, completely eliminates the tumor under laser irradiation and provokes a long-term antitumor immune memory effect. Conversely, a marginal effect is found if substituting OVA for bovine serum protein (BSA) in nanoparticle design or using MON to treat non-OVA expressing tumor. The antigen nanocarrier design promises to complement conventional PDT by boosting immune cascade, thereby leading to unique photodynamic immunotherapy.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  Antigen nano-assembly; Cell membrane camouflaging; Cross-presentation; Immunotherapy; Photodynamic therapy

Mesh:

Substances:

Year:  2020        PMID: 32200102     DOI: 10.1016/j.biomaterials.2020.119964

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  7 in total

Review 1.  Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells.

Authors:  Wojciech Szlasa; Natalia Janicka; Natalia Sauer; Olga Michel; Bernadetta Nowak; Jolanta Saczko; Julita Kulbacka
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

Review 2.  Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy.

Authors:  Bin Ji; Minjie Wei; Bin Yang
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

Review 3.  Emerging nanomedicines for effective breast cancer immunotherapy.

Authors:  Amirhossein Bahreyni; Yasir Mohamud; Honglin Luo
Journal:  J Nanobiotechnology       Date:  2020-12-09       Impact factor: 10.435

4.  Bacterial outer membrane vesicles-based therapeutic platform eradicates triple-negative breast tumor by combinational photodynamic/chemo-/immunotherapy.

Authors:  Yongjiang Li; Junyong Wu; Xiaohan Qiu; Suhe Dong; Jun He; Jihua Liu; Wenjie Xu; Si Huang; Xiongbin Hu; Da-Xiong Xiang
Journal:  Bioact Mater       Date:  2022-06-29

Review 5.  Tumor-Derived Membrane Vesicles: A Promising Tool for Personalized Immunotherapy.

Authors:  Jiabin Xu; Wenqiang Cao; Penglai Wang; Hong Liu
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-16

Review 6.  Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments.

Authors:  Qi Jiang; Mixue Xie; Ruyin Chen; Feifei Yan; Chanqi Ye; Qiong Li; Shuaishuai Xu; Wei Wu; Yunlu Jia; Peng Shen; Jian Ruan
Journal:  Front Immunol       Date:  2022-08-29       Impact factor: 8.786

7.  Engineering of Neutrophil Membrane Camouflaging Nanoparticles Realizes Targeted Drug Delivery for Amplified Antitumor Therapy.

Authors:  Jingshuai Wang; Xuemin Gu; Yiqin Ouyang; Lei Chu; Mengjiao Xu; Kun Wang; Xiaowen Tong
Journal:  Int J Nanomedicine       Date:  2021-02-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.